HC Wainwright Has Bearish Estimate for RMTI FY2026 Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Rockwell Medical in a research report issued on Friday, September 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.90) for the year, down from their prior estimate of ($0.76). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at $0.08 EPS and Q3 2027 earnings at $0.12 EPS.

A number of other equities analysts also recently issued reports on the stock. Weiss Ratings raised shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 3rd. Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Rockwell Medical has a consensus rating of “Hold” and an average price target of $20.00.

Rockwell Medical Trading Down 2.3%

Shares of RMTI opened at $7.78 on Tuesday. The firm’s 50-day moving average price is $7.17 and its 200-day moving average price is $7.83. The firm has a market capitalization of $31.35 million, a price-to-earnings ratio of -5.81 and a beta of 1.64. The company has a current ratio of 3.25, a quick ratio of 3.00 and a debt-to-equity ratio of 0.21. Rockwell Medical has a 1-year low of $4.89 and a 1-year high of $17.20.

Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Rockwell Medical had a negative return on equity of 14.03% and a negative net margin of 7.33%.The business had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $17.82 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Rockwell Medical stock. Renaissance Technologies LLC increased its holdings in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) by 36.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 639,120 shares of the company’s stock after acquiring an additional 170,800 shares during the period. Renaissance Technologies LLC owned approximately 1.62% of Rockwell Medical worth $571,000 at the end of the most recent reporting period. Institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.